Novartis AG (NYSE:NVS) Receives Consensus Rating of “Hold” from Brokerages

Novartis AG (NYSE:NVS) has been given an average rating of “Hold” by the ten research firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $93.34.

A number of equities research analysts have weighed in on NVS shares. Cowen reiterated a “buy” rating and issued a $100.00 target price on shares of Novartis in a report on Friday, October 25th. ValuEngine upgraded shares of Novartis from a “sell” rating to a “hold” rating in a research note on Saturday, October 19th.

A number of large investors have recently modified their holdings of NVS. Primecap Management Co. CA raised its holdings in shares of Novartis by 7.4% during the 2nd quarter. Primecap Management Co. CA now owns 25,617,640 shares of the company’s stock valued at $2,339,147,000 after buying an additional 1,760,424 shares in the last quarter. Bank of America Corp DE boosted its position in Novartis by 1.3% during the second quarter. Bank of America Corp DE now owns 9,166,269 shares of the company’s stock valued at $836,972,000 after buying an additional 115,613 shares during the period. Fisher Asset Management LLC grew its stake in shares of Novartis by 3.1% during the third quarter. Fisher Asset Management LLC now owns 8,314,984 shares of the company’s stock valued at $722,572,000 after buying an additional 247,749 shares during the last quarter. State Street Corp increased its holdings in shares of Novartis by 1.8% in the third quarter. State Street Corp now owns 2,721,543 shares of the company’s stock worth $236,502,000 after buying an additional 48,335 shares during the period. Finally, Parametric Portfolio Associates LLC increased its holdings in shares of Novartis by 2.5% in the third quarter. Parametric Portfolio Associates LLC now owns 2,538,794 shares of the company’s stock worth $220,621,000 after buying an additional 61,474 shares during the period. Hedge funds and other institutional investors own 10.62% of the company’s stock.

Novartis stock traded up $0.36 during mid-day trading on Thursday, reaching $94.96. 105,895 shares of the company were exchanged, compared to its average volume of 1,078,199. The firm has a market cap of $216.80 billion, a PE ratio of 18.66, a PEG ratio of 1.95 and a beta of 0.59. The company has a debt-to-equity ratio of 0.42, a current ratio of 0.95 and a quick ratio of 0.73. The company has a fifty day simple moving average of $93.65 and a 200-day simple moving average of $90.24. Novartis has a 12 month low of $74.70 and a 12 month high of $95.66.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 22nd. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.31 by $0.10. Novartis had a net margin of 24.43% and a return on equity of 20.86%. The firm had revenue of $12.17 billion for the quarter, compared to analyst estimates of $11.67 billion. During the same quarter last year, the business posted $1.32 earnings per share. The company’s quarterly revenue was up 10.5% on a year-over-year basis. Sell-side analysts anticipate that Novartis will post 5.23 earnings per share for the current year.

About Novartis

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Featured Story: Pattern Day Trader – What is the PDT Rule?

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply